Medicus Pharma Ltd. Common Stock
MDCXNASDAQHealthcareBiotechnology
Latest quote
$0.2726
−$0.0004 · -0.15%
MDCX company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Sell
Trim exposure — unfavorable risk-reward
Valuation
25
Expensive
Momentum
35
Weakening
Sentiment
51
Mixed
Risk resilience
37
High Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteMedicus Pharma Ltd., a biotechnology and life sciences enterprise, is dedicated to expediting the progression of innovative and groundbreaking medical treatments through their clinical development phases. A primary focus for the company is the creation of non-surgical solutions specifically targeting dermatological malignancies.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- CA
- CEO
- Raza Bokhari
- Listed since
- Nov 15, 2024
- Employees
- 16
Market position
- Volume
- 852.64K
- 0.39× average
- Average volume
- 2.16M
- Average daily volume
- Market cap
- 5.99M USD
- Beta
- -0.61
- Market reference 1
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 21.73M USD
- P/E (TTM)
- -0.14×
- P/B (TTM)
- -12.04×
- P/S (TTM)
- 0×
- EV / EBITDA
- -0.86×
- Earnings yield
- -95.92%
- Free cash flow yield
- -86.13%
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 0.00%
- Operating margin
- 0.00%
- Net margin
- 0.00%
- Return on equity
- 37549.85%
- Return on assets
- -252.12%
- Return on invested capital
- -452.42%
Financial health
- Debt / equity
- -12.27×
- Current ratio
- 1×
- Altman Z-score
- -7.47
- Piotroski F-score
- 2 of 9
Financial statements
Income trends
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Research and development | 7.72M USD | 3.53M USD | 193.58K USD | 646.38K USD | 1.18M USD |
| Selling, general, and administrative | 17.92M USD | 7.65M USD | 2.46M USD | 332.03K USD | 258.01K USD |
| Operating expenses | 18.35M USD | 11.18M USD | 4.73M USD | 978.42K USD | 1.44M USD |
| Interest income | — | 104.41K USD | 10.72K USD | −575.45K USD | −575.45K USD |
| Interest expense | 141.26K USD | 317.54K USD | 595.54K USD | 526.83K USD | 115.41K USD |
| Depreciation and amortization | — | — | 2.07M USD | — | — |
| Operating income | −18.35M USD | −11.18M USD | −4.73M USD | −978.42K USD | −1.44M USD |
| Net income | −25.37M USD | −11.16M USD | −5.31M USD | −1.69M USD | −2.06M USD |
Company facts updated Aug 24, 2026.
Earnings
- EPS beat rate
- 20%
- 2 beats, 8 misses, 0 met estimates
- Average EPS surprise
- -67.38%
- 10 comparable reports
- Latest EPS result
- -0.21
- Estimate -0.13 · Miss by 64.71%
EPS: actual versus estimate
Recent quarterly results
MDCX news
MDCX peers
Continue in GoAI
Research MDCXresearch.disclaimer